There are moments where a technology shifts how we think about treatment entirely. This is one of those moments.

HistoSonics’ Edison system introduces a completely different approach to treating tumors. Using histotripsy, a focused ultrasound technology, it mechanically destroys targeted tissue without surgery, heat, or radiation. That alone changes the conversation. But what stands out is what that enables.

There is no incision. Surrounding structures are preserved. Recovery looks different. The patient's experience looks different. And the pathway for using this across multiple organ systems continues to expand.

What started with liver tumors is already moving into additional applications, including the kidney and pancreas, with the potential to reach far beyond that.

This is not a single-indication story. It is a platform that introduces a new approach to treatment.

And when something like this works, when it proves itself clinically and begins to scale, it does more than improve outcomes. It changes expectations. For physicians. For patients. For the system as a whole.

From our vantage point, this is what defines a top innovator. Not just the technology itself, but the ability to open a new path forward.

Congratulations to HistoSonics, the winner of the TAG Award for Medical Devices – Top Innovator, recognized for redefining non-invasive tumor treatment and advancing a new frontier in care.